Fibromyalgia Market 5EU Drug Forecast and Market Analysis to 2023 "The Report Fibromyalgia 5EU Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. MarketResearchReports.biz" The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off label therapies. A handful of other genericized products also provide offlabel usage including antidepressants, antiepileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX102 SL, DS5565 and TD9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal. GlobalData estimates that the fibromyalgia market across the 5EU reached sales of approximately $149.7m in 2013. The EU market is expected to grow at a slower rate compared with the US, owing to a lack of approved brands and the fact that only one pipeline product is expected to enter the fibromyalgia market during the forecast period. Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/825701 Scope Overview of Fibromyalgia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in 5EU from 20132023. Analysis of the impact of key events as well the drivers and restraints affecting 5EU Fibromyalgia market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust
Fibromyalgia 5eu drug forecast and market analysis to 2023
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.